Antibodies assembled after RenLite discovery have a traditional antibody structure with properties that are advantageous for downstream CMC development.
The project will focus on new knowledge on the polymorphism of active ingredients and the advancement of methods for characterizing the solid state of their molecules.
Acquisition significantly enhances WuXi STA's drug product capacity in Europe and enhances capabilities by adding capacity to support global customers.
Bolsters offering in key strategic growth areas, including formulation chemistry, product manufacturing, extractables & leachables, and large molecule testing.
Learn how one CDMO is at the forefront of green chemistry, applying its principles to reduce the environmental and human impact of pharmaceutical production.